Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule by Awada, A et al.
Carzelesin (U-80,244, Figure 1A) is a cyclopropylpyrroloindole
(CPI) prodrug analogue of CC-1065. CC-1065 is a natural product
isolated from the soil organism Streptomyces zelensis, which
proved to be an extremely potent cytotoxic compound. However,
its clinical development as an antitumour agent was halted because
preclinical toxicology studies revealed that this agent caused
delayed fatal toxicity in mice and rabbits at sub-therapeutic doses
(McGovren et al, 1984). CPI drugs are a class of compounds with
unique DNA interactive properties. These agents fit into the minor
groove region of DNA, and the CPI function in the molecule
mediates a covalent binding to the N3 position of adenine in A-T
rich regions, thus forming DNA adducts in a sequence selective
fashion (Hurley et al, 1984; Reynolds et al, 1985).
Three new CPIs have now been developed. Adozelesin is most
closely related to CC-1065 as it already possesses the active CPI-
moiety (Figure 1A). Bizelesin differs from the classical CPI drugs
in that it contains two chloromethyl functions, which are both
converted (via intramolecular rearrangements) to the CPI alkyl-
ating species that interact with DNA. Consequently, this agent is
capable of forming DNA interstrand cross-links (Lee et al, 1991).
Carzelesin was designed to be an inactive prodrug as earlier
studies with CC-1065 had revealed that DNA alkylation by CPI
drugs occurred in a rapid fashion (Reynolds et al, 1985;
Warpehoski et al, 1988). Therefore, efforts were directed to modu-
late the alkylation rate by the preparation of CPI prodrugs that
would require chemical or enzymatic conversion. The activation
of Carzelesin is a two-step reaction with hydrolysis of the phenyl-
urethane substituent to form the intermediate compound U-76,073,
followed by ring closure to form the active product U-76,074
(Figure 1B). Although Carzelesin was found to be less potent than
adozelesin against tumour cells cultured in vitro, it proved to be
more efficacious in a broad panel of murine and human tumour
xenografts (Li et al, 1992). This higher efficacy may be related to
the pharmacologic features of the compound. Owing to the high
reactivity of the CPI moiety, the inactive prodrug may be able to
penetrate (target) tissues more effectively than an active CPI drug,
before conversion to the active compound.
In preclinical studies, Carzelesin was highly effective against
Lewis lung carcinoma, B16 melanoma, colon 38 carcinoma, colon
CX1 adenocarcinoma, lung LX-1 tumour, ovarian 2780 and
prostatic DU-145 carcinoma (Li et al, 1992; Houghton et al, 1995).
Carzelesin toxicity in preclinical studies occurred in bone marrow,
kidney, liver and spleen (EORTC-NDDO, 1992).
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Summary Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study,
Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients with advanced solid tumours. Patients received a median of two courses
(range 1–5) at one of nine dose levels: 24, 48, 96, 130, 150, 170, 210, 250 and 300 mg m–2. According to NCI-CTC criteria, non-
haematological toxicities (grade 1/2) included fever, nausea and vomiting, mucositis and anorexia, none of which was clearly dose related.
The dose-limiting toxicity was haematological and consisted mainly of neutropenia and to a lesser extent thrombocytopenia. From the dose
level 150 mg m–2, the haematological toxicity (particularly thrombocytopenia) was delayed in onset, prolonged and cumulative in some
patients. In several courses, double WBC nadirs occurred. The maximum tolerated dose for a single course was 300 mg m–2. From the dose
level 170 mg m–2, the intended dose intensity could not be delivered to most patients receiving > 2 courses owing to cumulative
haematological toxicity. The dose level with the best dose intensity for multiple courses was 150 mg m–2. The pharmacokinetics of Carzelesin
and its metabolites (U-76,073; U-76,074) have been established in 31 patients during the first course of treatment using a HPLC method.
Carzelesin exhibited linear pharmacokinetics. The concentration of U-76,074 (active metabolite) extended above the lower limit of
quantitation (1 ng ml–1) for short periods of time and only at the higher dose levels. There was no relationship between neutropenia and the
AUC of the prodrug Carzelesin, but the presence of detectable plasma levels of the active metabolite U-76,074 was usually associated with a
substantial decrease in ANC values.
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As all three compounds displayed promising results in preclin-
ical testing, they were selected for phase I testing. Two phase I
clinical trials with adozelesin have been completed in the USA
(Shamdas et al, 1994; Fleming et al, 1994). The phase I trial with
bizelesin is still in the planning stage by the NCI of the USA.
Carzelesin has been selected for clinical development in Europe
under the framework of the EORTC.
Co-ordinated by the EORTC-NDDO, two multicentre phase I
studies with Carzelesin were started in Europe. The patients received
the drug by a brief (10 min) IV infusion given once every 4 weeks or
in a daily ´ 5 schedule repeated every 4 weeks (Wolf et al, 1996).
In this report we describe the phase I clinical study with
Carzelesin administered as a single dose intravenously every 4
weeks. The aims of this study were to determine the toxic effects
of Carzelesin, the maximum tolerated dose (MTD), the pharmaco-
kinetics and to document any antitumour activity.
PATIENTS AND METHODS
Patient population
Patients with a histological diagnosis of solid tumour no longer
amenable to established forms of treatments were eligible. Other
inclusion criteria included: age 18–75 years, ECOG performance
status ≤ 2, white blood cell count ³ 4 ´ 109 l–1, platelet count
³ 100 ´ 109 l–1, bilirubin < 2 mg dl–1, serum creatinine ≤ 1.4 mg
dl–1, no clinical signs of brain involvement or leptomeningeal
disease, no prior chemotherapy or extended field radiotherapy for
at least 4 weeks prior to study entry. All patients gave written
informed consent and the protocol was approved by the Ethics
Committee of the two participating institutions as well as the
Protocol Review Committee of the EORTC.
Screening and follow-up studies
Prior to study, each patient underwent a complete history and
physical examination. Pretreatment laboratory investigations
included a complete blood count with leukocyte differential,
standard serum biochemistry and coagulation studies, urinalysis
and creatinine clearance, chest X-ray and electrocardiogram.
Appropriate radiological examinations for tumour measurements
were obtained before study entry. During the study, haematology
and biochemistry assessments were repeated weekly, or twice
weekly in all patients at that and subsequent doses following
significant haematological or biochemical toxicity (³ grade 2) in
any patient.
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Figure 1 (A) Molecular structures of CC-1065, adozelesin (U73,975), bizelesin (U77,779), carzelesin (U-80,244). (B) Molecular structures of carzelesin
(U-80,244), the intermediate metabolite U-76,073 and the active metabolite U-76,0741456 A Awada et al
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Treatment: starting dose, drug administration, drug
dose escalation
Preclinical toxicology in the mouse showed that the LD10 was
280 mg kg–1, which is equivalent to a MELD10 of 840 mg m–2. It is
generally accepted that 1/10 MELD10 provides a safe starting dose
for phase I clinical trials, as long as it is not toxic to a second
species, i.e. the rat. As for Carzelesin, a difference in species sensi-
tivity was seen, a dose level at 1/35 MELD10 was investigated in
toxicological studies and was considered as a safe starting dose for
human single-dose clinical trials. Therefore, the starting dose of
this phase I trial was 24 mg m–2.
Carzelesin was supplied by Pharmacia & Upjohn Company
(Kalamazoo, Michigan, USA) in 2-ml vials containing a drug
concentration of 250 mg ml–1 in a non-aqueous vehicle, comprised of
a 2:1 mixture of polyethylene glycol 400 and ethanol, with 10%
Tween 80 (PET) (Jonkman-de Vries et al, 1994). This pharmaceutical
preparation was kept frozen at – 30°C and protected against light.
For use the Carzelesin concentrate was diluted 10-fold with a
PET-vehicle to a concentration of 25 mg ml–1. Next, the appropriate
volume containing the prescribed dose was diluted with 5%
dextrose in water (D5W) to a final volume of 20 ml. Carzelesin
was administered using a PVC bag in one centre and a syringe
pump in the other, according to routine local practice. The drug
solution was infused intravenously at a dose rate of 2 ml min–1
(10 min infusion time). Carzelesin was administered every
4 weeks, with delays for toxicity recovery.
Doses were escalated in decreasing rates according to the
Fibonacci scheme and modified to reflect the emerging results of a
parallel phase I study (daily ´ 5 q 28 d) (Wolf et al, 1996). A
minimum of three patients receiving at least four evaluable courses
were to be evaluated at non-toxic dose levels. If significant (³ grade
II) toxicity was observed at a given dose level, more patients were
entered at that dose level. At each dose level, 1 week, or 2 weeks at
higher dose levels, was necessary between the entry of the first and
the next two patients. The dose limiting toxicity (DLT) was deter-
mined. The MTD was defined as the highest dose that can be safely
administered to a patient population producing, manageable and
reversible toxicity of CTC grade 3, or grade 4 in case of haemato-
logical toxicity in at least 2/6 patients. Discontinuation of treatment
was required for non-compliance of the patient, excessive toxicity
and progressive disease.
Assessment of toxicity and response
Patients were evaluable for toxicity if they received at least one
course of therapy. The evaluation period included all required
observations until recovery from all toxicities associated with the
first course of therapy. Toxicity was graded according to the
common toxicity criteria of the National Cancer Institute
(Bethesda, USA).
Patients were evaluable for antitumour activity if disease
measurements were performed over at least an 8-week period from
the first dose of therapy. Standard tumour measurement pro-
cedures were used including X-rays, CTscan, magnetic resonance
and ultrasound imaging. Response was to be classified according
to standard WHO criteria.
Pharmacokinetics–pharmacodynamics study
A detailed report of the clinical pharmacokinetics of Carzelesin
has been previously reported (Van Tellingen et al, 1998). In short,
the pharmacokinetics have been established in 31 patients enrolled
in this phase I study with at least two patients per dose level
sampled during their first course of chemotherapy. Plasma levels
of Carzelesin, and metabolites U-76,073 and U-76,074 (active
metabolite) were determined by a selective method based on high-
performance liquid chromatography (Van Tellingen et al, 1994a).
Plasma concentration vs. time curves were fitted using the
MW/Pharm software package. A one- or two-compartment infu-
sion model was used to calculate the distribution and elimination
half-lives of Carzelesin. The area under the concentration–time
curve (AUC) of Carzelesin, U-76,073 and U-76,074 was calcu-
lated using the linear trapezoidal rule. The pharmacodynamics of
the dose-limiting bone marrow toxicities were explored using plots
of percentage decrease (%decr) of granulocytes (ANC), white
blood cells (WBC) or platelets defined as
%decr = (pretreatment value – value of the nadir)/pretreatment
value ´ 100% vs. the AUC of Carzelesin or its active
metabolite (U-76,074)
RESULTS
Patient characteristics
Fifty-one eligible patients entered the trial from December 1992 to
October 1995. The demographic and treatment characteristics of
the study population are shown in Table 1.
Carzelesin administration
A total of nine dose levels up to 300 mg m–2 were investigated and
104 courses of Carzelesin were administered. The median number
of courses given was 2 (1–5). Table 2 summarizes the treatment
courses of Carzelesin.
Haematological toxicity
Eighty-one of 104 courses were evaluable for haematological
toxicity in 48 patients. Three patients were not evaluable owing to
Table 1 Patient characteristics (n = 51)
Male/female 34/17
Median age (range) 53 (21–71)
Median PS (range) 1 (0–2)
Previous therapy
Chemotherapy (CT) 25
Median no. of prior CT regimens (range) 2 (1–4)
Prior exposure to nitrosourea/mitomycin 7/1
Radiotherapy (RT) 3
CT + RT 21
No treatment 2
Tumour type
Colorectal 13
Melanoma 8
Head and neck 7
Sarcoma 5
Unknown origin 4
Renal 3
Other 11Phase I study of Carzelesin (U-80,244) 1457
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early disease progression (within 4 weeks of Carzelesin adminis-
tration) in two patients and lost to follow-up in one patient. Table 3
gives an overview of the Carzelesin myelotoxicity. Both
neutropenia and, to a lesser degree, thrombocytopenia were dose
limiting, showing a high interpatient variability at all dose levels
from 130 mg m–2 onwards and causing dose-delay and/or reduction
in several courses (Table 2). Consequently, the dose for further
phase II studies was determined taking into account not only the
level of myelotoxicity but also the actual dose intensity per course.
At the first two dose levels, no grade 3 or 4 haematological toxici-
ties were observed. At the dose levels 96 and 130 mg m–2, two
patients had grade 4 myelotoxicity. The intended dose intensity
(IDI) could be administered up to the dose level 130 mg m–2. At
150 mg m–2, two patients out of six evaluable patients developed
grade 4 myelotoxicity: the first patient, with renal cancer,
pretreated with interferon, IL6 and vinblastine, developed during
the first course grade 4 neutropenia and thrombocytopenia, with a
recovery on day 42 leading in the subsequent three courses to a
reduction of dose to 130 mg m–2; the second patient, with
colorectal cancer pretreated with 5FU and leucovorin, experienced
grade 4 neutropenia during the second course of treatment without
recovery by day 29. This showed that at 150 mg m–2 most patients
(four out of six) receiving ³ 2 courses were able to receive the
treatment at the scheduled time and dose, which was not possible
for the 170, 210, 250 and 300 mg m–2 dose levels (Table 2).
Moreover, at the dose level of 150 mg m–2, the median received
dose intensity was 37.5 mg m–2 week–1 (range: 27.3–37.5) and this
was equivalent to the IDI at this dose level. For this reason
150 mg m–2 every 4 weeks is recommended for further phase II
studies.
The doses of Carzelesin were further escalated in order to define
the MTD for a single course. This MTD was reached at
300 mg m–2, at which two out of four patients experienced grade 4
neutropenia, of whom one patient also had grade 4 thrombo-
cytopenia. This may be relevant for further studies in diseases
where grade 4 leuco- and thrombocytopenia are not considered
dose limiting (e.g. leukaemia).
Table 2 Carzelesin: treatment courses
Dose level No. of patients No. of courses No. of reduced No. of courses with delayed
(mg m–2) total/evaluable total/evaluable courses (dose level)a recovery (no. of pts)a
(n = 51)/(n = 48) (n = 104)/(n = 81) (n = 17) (n = 17)
24 4/4 6/6 0 0
48 3/3 9/7 0 0
96 5/5 8/8 0 0
130 6/5 10/9 0 0
150 6/6 17/14 3b (130) 3 (1)
170 11/9 19/16 0 4 (4)
210 7/7 16/10 6c (96, 105, 150) 5 (5)
250 5/5 13/7 6d (130, 170) 3 (3)
300 4/4 6/4 2e (150) 2 (2)
aDue to haematological toxicity (courses delayed for more than 3 days). b1 patient; c4 patients; d3 patients; e2 patients.
Table 3 Carzelesin: Grade 3/4 haematological toxicity
Dose level (mg m–2) 24 48 96 130 150 170 210 250 300
No. of evaluable patients/courses 4/6 3/7 5/8 5/9 6/14 9/16 7/10 5/7 4/4
No. of toxica patientsb courses 0 0 2/2 3/3 4/5 6/8 5/6 2/3 3/3
Neutropenia grade 3/4
No.b of patients 0 0 0/1 2/0 1/2 1/3 2/3 0/2 1/2
No. of courses 0 0 0/1 2/0 2/2 1/3 3/3 1/2 1/2
Thrombocytopenia grade 3/4
No.b of patients 0 0 1/0 2/1 1/1 3/2 0/2c 1/1 1/1
No. of courses 0 0 1/0 2/1 1/1 5/2 0/2 1/1 1/1
No. of toxic patients following the 0 0 2 0 2 4 4 2 3
first coursea
Neutropenia grade 3/4 0 0 0/1 0 0/1 0/2 3/1 1/1 1/2
Thrombocytopenia grade 3/4 0 0 1/0 0 1/1 3/0 0/1c 1/0 1/1
aGrade 3/4 neutropenia and/or thrombocytopenia. bWorst grade per patient. cOne patient had a pre-existing grade 1 thrombocytopenia.
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Overall, the haematological toxicity was delayed in onset
[median days to nadir were 12 (8–14) for neutrophils and 20
(15–26) for platelets], prolonged [median days to complete
recovery were 28 (20–35) for neutrophils and 33 (24–56) for
platelets] and appeared to be cumulative in some patients. Of note,
from the dose level of 130 mg m–2, a second drop in the leucocyte
and neutrophil count after an apparent recovery was seen in 33%
of evaluable patients and in 26% of evaluable courses (Figure 2).
These ‘second nadirs’ caused a delay of treatment for the next
courses and, consequently, a decrease in Carzelesin dose intensity.
Nine patients treated at different dose levels (from 130 mg m–2)
received red cell transfusions while on study. In general, these
patients had mild pre-existing anaemia which worsened during
treatment. No haemorrhagic episodes were noted during treatment
with Carzelesin, in spite of the fact that thrombocytopenia was
prolonged and dose limiting. One patient treated at the dose level
of 250 mg m–2 experienced an episode of febrile neutropenia. This
patient was successfully treated with IV antibiotics and G-CSF.
Non-haematological toxicities
Treatment with Carzelesin was generally well tolerated and non-
haematological toxicities were infrequent and mild. Grade 1–2
fever, nausea/vomiting, mucositis, allergic reactions, anorexia and
phlebitis were observed, none of which was clearly dose related.
Table 4 summarizes non-haematological toxicities seen for the
dose levels 150–300 mg m–2 combined. A flush reaction was
reported in five patients and, in two of these, drug administration
was extended to 20 min.
Pharmacokinetics–pharmacodynamics results
Of the 51 patients in this study, 31 were sampled for pharmaco-
kinetic monitoring and evaluable for exploring pharmacokinetic–
pharmacodynamic relationships. The results of the pharmaco-
kinetic behaviour of Carzelesin and its major metabolites have
been reported in detail elsewhere (Van Tellingen et al, 1998). In
summary, the analytical method was sufficiently sensitive to estab-
lish a plasma concentration–time profile of Carzelesin from the
first dose level of 24 mg m–2 (Van Tellingen et al, 1994a). The peak
plasma concentration at this dose was about 10 ng ml–1 and the
plasma level dropped to below 1 ng ml–1 within 1 h after drug
administration. At the highest dose level of 300 mg m–2, the mean
peak plasma levels of Carzelesin was 63 ng ml–1, whereas the
mean concentrations of the metabolites U-76,073 and U-76,074
were 18 and 3 ng ml–1 respectively. From the dose level 96 mg m–2,
the concentration of the active metabolite U-76,074 ranged
between 1 and 2 ng ml–1 in the majority of the patients and, owing
to these low plasma levels of U-76,074, it was not possible to
calculate the elimination half-life of this metabolite, whereas the
elimination half-life of Carzelesin was 23 ± 9 min (mean ± SD).
Overall, there was a good correlation between the dose and the
plasma AUC of Carzelesin, indicating linear pharmacokinetics.
The pharmacokinetic–pharmacodynamic relationships are
depicted in Figure 3. The correlation between the AUC of
Carzelesin vs the %decr in WBC, ANC or platelets was poor.
However, the finding of detectable plasma levels of the active
compound U-76,074 was usually associated with a greater than
60% decrease in ANC values. Only one patient was an exception
to this finding: this patient, treated at 300 mg m–2, experienced very
modest toxicity, despite the fact that he also had the highest AUC
of Carzelesin in this study. When this patient received the second
course of treatment, the %decr in ANC was 82%.
Antitumor activity
Eight patients were not evaluable for response. Thirty-four
patients had progressive disease and nine patients had stable
disease as best overall response.
DISCUSSION
The CPI analogues are DNA minor groove binders containing a
cyclopropyl group which mediates N3-adenine covalent adduct
formation in a sequence selective fashion (D’Incalci, 1994).
Adozelesin (U-73,975), Carzelesin (U-80,244) and Bizelesin
(U-77,779) are three agents of this family.
In this study, Carzelesin was given as a 4-weekly 10-min i.v.
infusion to 51 patients with solid tumours. Haematological toxicity
(neutropenia and to a lesser degree thrombocytopenia) was the only
dose-limiting toxicity. It was delayed in onset (particularly for
thrombocytopenia), prolonged and cumulative in some patients.
The dose level with the best dose intensity for multiple courses was
150 mg m–2 once every 4 weeks. This dose was selected for phase II
Table 4 Carzelesin: non-haematological toxicities in 31 evaluable patients(a)
Toxicity Worst CTC-grade per patient
12 3 4
Bilirubin NA 6 1 0
Creatinine 6 1 0 0
Proteinuria 3 0 0 0
Nausea 11 6 2 0
Vomiting 7 5 2 0
Diarrhoea 5 1 0 1b
Fatigue/asthenia 3 9 3 0
Fever 4 5 2 0
Pain at the infusion site 9 2 0 0
Mucositis 7 1 0 0
Anorexia 5 5 0 0
NA = not applicable. aToxicities seen for the dose levels: 150, 170, 210, 250, 300 mg m–2 combined. bThe relation to Carzelesin was unlikely.Phase I study of Carzelesin (U-80,244) 1459
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Figure 3 Scatter plots of bone marrow toxicity depicted as %decr in white blood cells (WBC), granulocytes (ANC), and platelets vs. AUCs of Carzelesin and its
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studies which are presently ongoing in different tumour types
within the framework of the EORTC-ECSG.
Carzelesin was also investigated in 25 patients with solid
tumours using a daily times five schedule in another EORTC-
ECSG study. With this schedule, the MTD was 40 mg m–2 day–1,
and 35 mg m–2 (‘good risk’ patients) and 30 mg m–2 (‘poor risk’
patients), daily for 5 consecutive days every 4–5 weeks, were the
recommended doses for phase II studies (Wolf et al, 1996).
Concerning dose intensity on a mg m–2 week–1 basis, this schedule
seems to offer no advantage over the day 1 every 4 weeks schedule
studied in our study.
Carzelesin showed a pattern of myelotoxicity comparable with
that of Adozelesin, the first CPI analogue which completed phase I
and II evaluations (Shamdas et al, 1994; Fleming et al, 1994) but a
less favourable pattern of myelotoxicity than another DNA-minor-
groove alkylating agent, Tallimustine (distamycin derivative). In
fact, Tallimustine given in a day 1 q 4 weeks schedule had a brief
neutropenia as dose-limiting toxicity (Sessa et al, 1994).
The toxicity profile of Carzelesin is relatively specific to the
bone marrow, providing a rationale for investigating this agent in
haematological tumours, and in particular, in leukaemia patients.
Since the dose-limiting toxicity of Carzelesin is bone marrow
suppression, we investigated the relationship between drug exposi-
tion (AUC of Carzelesin) and the percentage decrease in WBCs,
ANC and platelets. Since CPI drugs exert their cytotoxicity by
DNA adduct formation, we expected to find a relationship
between drug exposure and toxicity. However, this relationship
was very poor (Figure 3). In fact, the patient with the highest AUC
observed in this series (viz. 43.2 ng ml.h–1) experienced only very
modest toxicity, whereas a marked toxicity was found in other
patients with an AUC of less than 20 ng ml.h–1. Since we already
showed that there was a good correlation between the AUC of
Carzelesin and the Cmax of Carzelesin and a similar good correla-
tion between the AUC of Carzelesin and the AUC of the inter-
mediate metabolite U-76,073 (Van Tellingen et al, 1998), we did
not plot the %decr of the blood cells separately against these two
parameters. On the other hand, since Carzelesin is a prodrug and
U-76,074 the active CPI species, we explored the relationship
between the AUC of this active compound and toxicity. Although
there remains a substantial scatter in the data, it is noteworthy that
a substantial decrease in ANC (i.e. > 60%) occurred mainly in
patients whose plasma levels of U-76,074 exceeded 1 ng ml–1 for
some time. Only three patients with lower plasma levels of U-
76,074 presented with a greater that 60% decrease in ANC values.
Although the use of U-76,074 levels to predict toxicity may
seem attractive, it is important to realize that this parameter may be
potentially flawed by two factors. Firstly, Carzelesin is converted
to U-76,074 in the central blood compartment as well as intracellu-
larly and, although this latter component may be even more impor-
tant for the extent of myelotoxicity, it cannot be determined by
measurement of plasma levels. Secondly, Carzelesin is readily
converted to U-76,074 ex vivo if the sample is not immediately
cooled in ice-water. Although much attention has been paid to
warrant proper handling of the blood samples drawn from patients,
it is not possible to exclude fully a contribution of ex vivo forma-
tion of U-76,074 in the levels determined by HPLC. It is obvious
that pharmacokinetic–pharmacodynamic relationships need to be
validated more extensively before they can be used in the clinic to
predict toxicity.
The plasma level of the active metabolite U-76,074 extended
above 1 ng ml–1 for short periods of time in most patients receiving
a dose of 130 mg m–2 or higher. However, it is not clear which
levels of U-76,074 are sufficiently high to induce an antitumour
response in patients. Although the achieved concentrations are
well above the concentration required to produce more than 50%
tumour cell kill (IC50 in in vitro cell cultures (Li et al, 1992), these
levels are much lower than achieved in mice receiving this drug at
the MTD (Van Tellingen et al, 1994b). Furthermore, recent results
with tumour-bearing mice suggest that the dose–response curve is
very steep (Houghton et al, 1995): indeed, when the dose was
lowered to 50% of the MTD, the antitumour efficacy was signifi-
cantly reduced. The profound haematologic toxicity of Carzelesin
may obstruct the achievement of plasma levels required for antitu-
mour activity. However, the final answer regarding the activity of
this compound will be given by the ongoing phase II clinical
studies.
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